| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
this paper reviews 19 studies that examine the cognitive effects of cannabis on schizophrenia by comparing cognitive functioning of cannabis-using and non-using schizophrenia patients across a vast range of domains (memory, attention and processing speed, executive functions, visuospatial, psychomotor and language). |
2013-03-25 |
2023-08-12 |
Not clear |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
the inconsistencies in the studies reviewed may stem from significant methodological variance between the studies regarding patient selection, adequate controls, cognitive measures used, measures of cannabis use, additional drugs used, and clinical aspects of schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| Floor J van der Meer, Eva Velthorst, Carin J Meijer, Marise W J Machielsen, Lieuwe de Haa. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716158. |
a series of meta-analytic reviews reveal a robust association between cannabis use and the development of psychosis and schizophrenia. |
2013-03-25 |
2023-08-12 |
human |
| Erica Zamberletti, Tiziana Rubino, Daniela Parolar. The endocannabinoid system and schizophrenia: integration of evidence. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716159. |
another important aspect in studying the relationship between the endocannabinoid system and schizophrenia is the impact of cannabis consumption on psychotic disorders, especially when this occurs at vulnerable ages such as adolescence. |
2013-03-25 |
2023-08-12 |
human |
| P D Morrison, J M Ston. Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Human psychopharmacology. vol 26. issue 1. 2013-03-08. PMID:23055415. |
it is unknown if cannabis recreates the negative symptoms of schizophrenia. |
2013-03-08 |
2023-08-12 |
Not clear |
| F M Leweke, D Piomelli, F Pahlisch, D Muhl, C W Gerth, C Hoyer, J Klosterkötter, M Hellmich, D Koeth. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry. vol 2. 2013-03-04. PMID:22832859. |
cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. |
2013-03-04 |
2023-08-12 |
Not clear |
| F M Leweke, D Piomelli, F Pahlisch, D Muhl, C W Gerth, C Hoyer, J Klosterkötter, M Hellmich, D Koeth. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry. vol 2. 2013-03-04. PMID:22832859. |
in our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. |
2013-03-04 |
2023-08-12 |
Not clear |
| F M Leweke, D Piomelli, F Pahlisch, D Muhl, C W Gerth, C Hoyer, J Klosterkötter, M Hellmich, D Koeth. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry. vol 2. 2013-03-04. PMID:22832859. |
the results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia. |
2013-03-04 |
2023-08-12 |
Not clear |
| Tim Karl, Jonathon C Arnol. What does a mouse tell us about neuregulin 1-cannabis interactions? Frontiers in cellular neuroscience. vol 7. 2013-03-01. PMID:23447438. |
it has been hypothesized that schizophrenia patients carrying particular risk genes might be more sensitive to the psychosis-inducing effects of cannabis than other patients and healthy test subjects. |
2013-03-01 |
2023-08-12 |
mouse |
| Jarrah R Spencer, Keturah M E Darbyshire, Aurelie A Boucher, Mohammed A Kashem, Leonora E Long, Iain S McGregor, Tim Karl, Jonathon C Arnol. Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Frontiers in cellular neuroscience. vol 7. 2013-03-01. PMID:23447498. |
neuregulin 1 (nrg1) is linked to an increased risk of developing schizophrenia and cannabis dependence. |
2013-03-01 |
2023-08-12 |
mouse |
| David J Castl. Cannabis and psychosis: what causes what? F1000 medicine reports. vol 5. 2013-01-31. PMID:23361396. |
increasing evidence suggests that early and heavy cannabis exposure may increase the risk of developing a psychotic disorder such as schizophrenia. |
2013-01-31 |
2023-08-12 |
Not clear |
| David J Castl. Cannabis and psychosis: what causes what? F1000 medicine reports. vol 5. 2013-01-31. PMID:23361396. |
the relationship between cannabis exposure and schizophrenia fulfills some, but not all, of the usual criteria for causality. |
2013-01-31 |
2023-08-12 |
Not clear |
| David J Castl. Cannabis and psychosis: what causes what? F1000 medicine reports. vol 5. 2013-01-31. PMID:23361396. |
however, most people who use cannabis do not develop schizophrenia, and many people diagnosed with schizophrenia have never used cannabis. |
2013-01-31 |
2023-08-12 |
Not clear |
| David J Castl. Cannabis and psychosis: what causes what? F1000 medicine reports. vol 5. 2013-01-31. PMID:23361396. |
therefore, it is likely that cannabis exposure is a "component cause" that interacts with other factors to "cause" schizophrenia or other psychotic disorders, but is neither necessary nor sufficient to do so alone. |
2013-01-31 |
2023-08-12 |
Not clear |
| Suzanne H Gage, Stanley Zammit, Matthew Hickma. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 medicine reports. vol 5. 2013-01-31. PMID:23361397. |
stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. |
2013-01-31 |
2023-08-12 |
Not clear |
| Suzanne H Gage, Stanley Zammit, Matthew Hickma. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 medicine reports. vol 5. 2013-01-31. PMID:23361397. |
cannabis use can acutely induce psychotic experiences, but its causal relationship to schizophrenia is less well understood. |
2013-01-31 |
2023-08-12 |
Not clear |
| Suzanne H Gage, Stanley Zammit, Matthew Hickma. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 medicine reports. vol 5. 2013-01-31. PMID:23361397. |
this is especially important as ecological studies have found little association between the increase in cannabis use over recent decades and incidence of psychotic disorders; public health models suggest that cannabis use may need to be treated and prevented in many thousands of users in order to prevent one case of schizophrenia. |
2013-01-31 |
2023-08-12 |
Not clear |
| Suzanne H Gage, Stanley Zammit, Matthew Hickma. Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 medicine reports. vol 5. 2013-01-31. PMID:23361397. |
we believe that, while such uncertainty exists, there is a scientific duty to continue to investigate the role of cannabis in the aetiology of schizophrenia and that the policy case for considering cannabis exposure as a critical target for preventing schizophrenia is yet to be made. |
2013-01-31 |
2023-08-12 |
Not clear |
| Krzysztof Krysta, Irena Krupka-Matuszczyk, Małgorzata Janas-Kozik, Małgorzata Stachowicz, Jan Szymszal, Janusz K Rybakowsk. Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis. Medical science monitor : international medical journal of experimental and clinical research. vol 18. issue 9. 2013-01-08. PMID:22936195. |
inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis. |
2013-01-08 |
2023-08-12 |
Not clear |
| Verity C Leeson, Isobel Harrison, Maria A Ron, Thomas R E Barnes, Eileen M Joyc. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophrenia bulletin. vol 38. issue 4. 2012-12-27. PMID:21389110. |
the effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. |
2012-12-27 |
2023-08-12 |
Not clear |